Shares in Faron Pharmaceuticals Limited (AIM:FARN) climbed 6% after the company reported "remarkable" trial data for its lead drug, bexmarilimab, being tested for myelodysplastic syndrome (MDS), a rare and aggressive blood cancer.
In the ongoing Phase II BEXMAB study, 80% of patients responded positively to a combination of bexmarilimab and azacitidine, a significant improvement over the typical 0-20% response rate seen with existing treatments.
Atlantic Lithium Ltd (AIM:ALL, OTCQX:ALLIF, ASX:A11) announced on Tuesday that its funding partner Piedmont Lithium (ASX:PLL, OTC:PLLTL) is merging with Aussie-listed Sayona Mining
After the merger is closed, the new entity will be in charge of US$70 million in funding towards the development expenditure of Atlantic’s flagship Ewoyya project in Ghana.
HeLIX Exploration PLC (AIM:HEX) has announced a disappointing result from testing a secondary target in its Clink-1, which yielded a discovery in the primary target earlier this month.
Testing in the Amsden formation found sub-economic levels of helium, the company said.
Cordiant Digital Infrastructure Ltd (LSE:CORD) has increased its interim dividend after posting a confident first-half financial performance for the six months to 30 September.
The London-listed investment company, which owns a portfolio of telecoms and data centre assets spread across Europe, achieved a 15.2% year-on-year increase in aggregate EBITDA to £77.4 million.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has commenced a phase III trial to test the long-term safety and effectiveness of its Grass MATA MPL allergy treatment in children.
This marks the first industry trial of its kind for paediatric patients with grass pollen-induced allergic rhinitis.
Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen described the latest data read-out from its lead asset as' remarkable'.
Specifically, he was referring to the overall response rate (ORR) to bexmarilimab, which increased as the number of patients added to the latest clinical trial expanded.